A5093530221- Diabetes Treatment and Management
- Potassium and Related Disorders
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Metabolism, Diabetes, and Cancer
- Adenosine and Purinergic Signaling
- Heart Failure Treatment and Management
Hamad Medical Corporation
2024-2025
Despite its pivotal role in drug metabolism, the exact consequences of rising medica-tions count from various therapeutic classes on mortality outcomes amongst patients with chronic liver disease remains unexplored. In this study, we investigated effect different polypharmacy phenotypes clinical including length hospitalization, need for intensive care admission, and (CLD). Methods: This retrospective cohort study examined impact receiving at tertiary centres within Weill Cornell...
Background Acute coronary syndrome (ACS) remains a risk factor for heart failure (HF). Therefore, we aimed to assess the cardioprotective role of sodium–glucose cotransporter-2 (SGLT2) inhibitors post-ACS in patients with acute HF (AHF) and diabetes. Methods We conducted retrospective observational cohort study employing propensity score matching. This involved diabetes admitted ACS complicated by AHF, defined as either new clinical requiring diuretics during index admission or having an...
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have cardio-renal protection benefits regardless of diabetes status. However, the outcomes uninterrupted SGLT2i use peri-percutaneous coronary intervention (PCI) among patients with acute syndrome (ACS) remain uncertain. Therefore, this study aimed to evaluate safety peri-PCI. Methods: We conducted a retrospective observational cohort that included all admitted ACS who underwent revascularization PCI at Qatar's main tertiary...
Introduction: Patients with acute coronary syndrome (ACS) have an unmet need for further risk reduction in major adverse cardiovascular events (MACE) and heart failure (HF) development despite guideline-directed medical therapy. As sodium glucose cotransporter-2 inhibitors (SGLT2i) are cardioprotective, this study, we assessed the effectiveness of SGLT2i post-ACS new onset HF. Hypothesis: use improves outcomes induced Methods: We conducted a retrospective observational cohort study that...